ArticleBMC public health2026
Association between sarcopenic obesity and kidney stones: evidence from a prospective cohort study on the UK Biobank.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between handgrip strength and visceral obesity with low appendicular skeletal muscle mass in Chinese adults.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundsKidney stone disease (KSD) is closely linked to metabolic disturbances, and sarcopenic obesity (SO) has been proven as a risk factor in multiple diseases. This study is to probe the prospective association and potential mediators between SO and KSD.
methodsWe conducted a prospective cohort analysis of 157,505 participants from the UK Biobank. The primary exposure was SO, defined by body mass index, handgrip strength, and muscle mass. Participants were classified as control group, obesity alone, sarcopenia alone, and SO group. The primary outcomes were the incidence and onset time of KSD. The potential mediators were multiple insulin resistance-related indexes and inflammatory markers. The models adjusted for social characteristics, personal lifestyle habits, dietary factors, blood biochemistry, and baseline disease history. We applied Cox regression models, cumulative incidence curves, sensitivity analysis, hierarchical and interaction analysis, and mediation analysis to probe these associations.
resultsAmong the 157,505 participants, 7,501 (4.76%) had sarcopenia alone, 1,407 (0.89%) had SO, and 1,592 participants (1.01%) developed KSD. In cumulative incidence curves, compared with the control group, a higher incidence of KSD was observed in the SO group. In fully adjusted models, the incident KSD risk was elevated by 48% (95%CI:1.32–1.67), 33% (95% CI: 1.05–1.68), and 83% (95% CI: 1.26–2.67) in the obesity alone group, sarcopenia alone group, and SO group, respectively. Four sensitivity analyses yielded consistent results. In different genders and ages, the increased risk of KSD associated with SO shows some differences: in females, males, participants aged < 60 and ≥ 60 years old, the KSD risk in participants with SO increased by 108% (95%CI:1.18–3.68), 69% (95%CI:1.02–2.80), 103%(95%CI:1.23–3.33), and 61% (95%CI:0.90–2.88), respectively. Triglyceride-glucose (TyG), triglyceride/high-density lipoprotein cholesterol (TG/HDL-C), neutrophil, white blood cell (WBC), C-reactive protein (CRP), monocyte, and CRP-to-Albumin ratio (CAR) partially mediate the association between SO and KSD, with proportions mediated (PM) of 11.2%, 7.2%, 4.5%, 2.7%, 8.7%, 1.2%, and 8.9%, respectively (all P < 0.01).
conclusionsSarcopenia and SO are significantly associated with an elevated incident KSD risk. Insulin resistance and inflammation play a significant partial mediating effect between SO and KSD. Participants with SO should pay attention to the prevention of kidney stones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.